Announcements Trials
Browse Landscape

Phase

Phase 1 3Phase 2 2

Status

Completed 28Terminated 5Withdrawn 1

Sponsor Class

INDUSTRY 4OTHER 1

Study Type

Interventional 5

Sponsor

Cancer Type

Thoracic 2Other solid neoplasm 1Gynecologic 1Gastrointestinal 1

Conditions

Carcinoma, Non-Small-Cell Lung 2Solid Tumors 1Ovarian Neoplasms 1Neoplasms 1Fallopian Tube Neoplasms 1Colorectal Neoplasms 1Advanced Cancers 1

Interventions

Cyclophosphamide 390Carboplatin 344Gemcitabine 332pembrolizumab 329Cisplatin 328Paclitaxel 297Radiotherapy 296Docetaxel 286Bevacizumab 253Rituximab 234Capecitabine 223Nivolumab 220Dexamethasone 206Fluorouracil 190fludarabine 177Oxaliplatin 177Pemetrexed 153Doxorubicin 153Irinotecan 148Leucovorin 144Etoposide 144Cytarabine 133Cetuximab 129Bortezomib 129fludarabine phosphate 128Lenalidomide 126Erlotinib Hydrochloride 120Filgrastim 119Temozolomide 113Radiosurgery 113

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Terminated × ridaforolimus × Clear all
NCT01212627 2021-02-16

Ridaforolimus With Cetuximab: Adv Non-Small Cell Lung, Colorectal, Head & Neck Cancer

Brown University

Phase 1 Terminated
12 enrolled 7 charts
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT01431534 2019-03-01

MK-8669-056

Merck Sharp & Dohme LLC

Phase 1 Terminated
20 enrolled 10 charts
Other solid neoplasm

Solid Tumors

NCT00836927 2019-02-18

MK-8669-038

Merck Sharp & Dohme LLC

Phase 2 Terminated
7 enrolled 13 charts

Advanced Cancers

NCT01243762 2018-08-16

A Study of Dalotuzumab + MK-2206, Dalotuzumab + MK-0752, and Dalotuzumab + Ridaforolimus Combination Therapies in Participants With Advanced Cancer (MK-0646-027)

Merck Sharp & Dohme LLC

Phase 1 Terminated
47 enrolled 12 charts
GastrointestinalGynecologic

Fallopian Tube Neoplasms, Neoplasms, Ovarian Neoplasms, Colorectal Neoplasms

NCT00818675 2015-01-21

A Study of Ridaforolimus in Non-Small Cell Lung Cancer (NSCLC) Patients With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutations (MK-8669-021 AM1)

Merck Sharp & Dohme LLC

Phase 2 Terminated
80 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡